Insights

On October 30, 2017 Cerus Corp. announced that it has entered into a two-year supply contract with Centro de Transfusion de la Comunidad de Madrid (CTCM) for the INTERCEPT^TM Blood System for platelets.

The French Ministry of Health decided late 2016 that platelet pathogen inactivation should be deployed throughout the entire French territory for the control of bacterial infections transmitted by transfusion, following the recommendations of the National Agency for the Safety of Medicines and Health Products (ANSM).

In 1982 was an epidemic of HIV in San Francisco. 300 patients acquired HIV infections from blood transfusions. The patients did not blame the hospital, but simply asked “Do something about it”. This request became the personal motivation of M.D. Larry Corash to found Cerus.

For blood centres seeking a cost-effective way to implement INTERCEPT^TM pathogen inactivation, double dose buffy coat platelet production may offer a solution.

What is a double dose buffy coat platelet unit?

A platelet concentrate with sufficient platelet count to result in 2 therapeutic doses after pathogen inactivation with the INTERCEPT Blood System.

The double dose buffy coat platelet...

Large Austrian Medical Centre publishes study results on component utilization and patient safety after adoption of platelet pathogen inactivation.

The Medical University Hospital in Innsbruck has evaluated the influence of the INTERCEPT™ Blood System for platelets on component utilization and patient safety. The effectiveness of conventional vs. INTERCEPT™-treated platelets was analyzed during...